{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968916",
  "id": "02968916",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0914",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrv4v0bc51sx.pdf",
  "summary": "### Summary of ASX Announcement \u2013 Nyrada Inc. (ASX:NYR)  \n\n**Type:** Clinical Trial Update  \n\n#### **Material Information:**  \n- **Final Cohort Approved:** Cohort 6 of Phase I clinical trial for **Xolatryp\u2122** cleared to commence, marking the trial's last stage.  \n- **Safety Data:** No safety concerns, dose-limiting toxicities, or adverse effects reported in Cohort 5 (highest concentration tested to date, 3-hour IV infusion).  \n- **Dose Escalation:** Cohort 6 will administer the same concentration as Cohort 5 but with a **6-hour infusion** (doubling total exposure).  \n- **Trial Timeline:** Final readouts expected in **September 2025 quarter**.  \n- **Preclinical Efficacy:**  \n  - **Cardioprotection:** 42% efficacy in preclinical coronary heart disease study (May 2025).  \n  - **Neuroprotection:** Statistically significant results in traumatic brain injury (April 2025) and stroke models (February 2024).  \n\nNo material capital markets or financing updates identified. Focus remains on clinical progress.",
  "usage": {
    "prompt_tokens": 2286,
    "completion_tokens": 236,
    "total_tokens": 2522,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T23:32:20.283066"
}